Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
PV For Newbies – A Patient’s Perspective
Publisher’s Update – April 2026 This article was originally published in 2015 and remains a helpful overview for newly diagnosed PV patients. One important treatment update: since publication, the FDA has approved Besremi (ropeginterferon alfa-2b) for polycythemia vera. Besremi is a next-generation, long-acting interferon administered every two weeks and is the first interferon specifically FDA-approved […]
